Mark A. Dawson

18.8k total citations · 6 hit papers
86 papers, 7.5k citations indexed

About

Mark A. Dawson is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Mark A. Dawson has authored 86 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 25 papers in Hematology and 20 papers in Genetics. Recurrent topics in Mark A. Dawson's work include Epigenetics and DNA Methylation (21 papers), Protein Degradation and Inhibitors (18 papers) and Acute Myeloid Leukemia Research (14 papers). Mark A. Dawson is often cited by papers focused on Epigenetics and DNA Methylation (21 papers), Protein Degradation and Inhibitors (18 papers) and Acute Myeloid Leukemia Research (14 papers). Mark A. Dawson collaborates with scholars based in Australia, United Kingdom and United States. Mark A. Dawson's co-authors include Tony Kouzarides, Andrew J. Bannister, Sarah‐Jane Dawson, Berthold Göttgens, Jean‐Christophe Marine, Ricky W. Johnstone, Paul A. Beavis, Simon J. Hogg, Brian J.P. Huntly and Anthony R. Green and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Mark A. Dawson

78 papers receiving 7.4k citations

Hit Papers

Cancer Epigenetics: From Mechanism to Therapy 2009 2026 2014 2020 2012 2020 2009 2019 2020 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cancer Epigenetics: From Mechanism to Therapy
    2012 2.3k citations Mark A. Dawson, Tony Kouzarides profile →
  2. Targeting the epigenetic regulation of antitumour immunity
    2020 461 citations Simon J. Hogg, Paul A. Beavis et al. Nature Reviews Drug Discovery profile →
  3. JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
    2009 451 citations Mark A. Dawson, Andrew J. Bannister et al. profile →
  4. The roles of DNA, RNA and histone methylation in ageing and cancer
    2019 383 citations Andrew J. Bannister, Mark A. Dawson et al. profile →
  5. Non-genetic mechanisms of therapeutic resistance in cancer
    2020 353 citations Jean‐Christophe Marine, Sarah‐Jane Dawson et al. Nature reviews. Cancer profile →
  6. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
    2018 274 citations Constantine S. Tam, Mary Ann Anderson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark A. Dawson Australia 33 5.7k 1.3k 1.2k 1.2k 832 86 7.5k
Jordan S. Fridman United States 22 3.6k 0.6× 2.0k 1.5× 679 0.6× 1.0k 0.9× 1.0k 1.2× 41 6.0k
Richard B. Lock Australia 53 5.1k 0.9× 2.8k 2.1× 1.2k 1.0× 1.6k 1.4× 596 0.7× 260 8.7k
Donald L. Durden United States 38 3.3k 0.6× 1.1k 0.9× 1.0k 0.8× 543 0.5× 776 0.9× 108 5.3k
Joel Johansson United States 34 4.3k 0.7× 1.8k 1.4× 512 0.4× 1.1k 1.0× 651 0.8× 93 6.0k
Alwin Krämer Germany 39 4.0k 0.7× 2.2k 1.6× 814 0.7× 835 0.7× 395 0.5× 124 5.9k
Peter Atadja United States 58 9.5k 1.7× 2.6k 2.0× 910 0.8× 1.8k 1.6× 582 0.7× 150 11.2k
Edward A. Fox United States 33 4.8k 0.8× 1.7k 1.3× 1.2k 1.0× 1.0k 0.9× 662 0.8× 53 7.4k
Isidro Sánchez‐García Spain 36 2.7k 0.5× 1.3k 1.0× 669 0.6× 693 0.6× 465 0.6× 115 4.4k
Domenico Delia Italy 43 4.2k 0.7× 2.5k 1.9× 1.2k 1.0× 438 0.4× 447 0.5× 125 6.9k
Selina Chen‐Kiang United States 47 3.4k 0.6× 2.6k 2.0× 766 0.6× 1.1k 0.9× 869 1.0× 147 6.6k

Countries citing papers authored by Mark A. Dawson

Since Specialization
Citations

This map shows the geographic impact of Mark A. Dawson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Dawson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Dawson more than expected).

Fields of papers citing papers by Mark A. Dawson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Dawson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Dawson. The network helps show where Mark A. Dawson may publish in the future.

Co-authorship network of co-authors of Mark A. Dawson

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Dawson. A scholar is included among the top collaborators of Mark A. Dawson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Dawson. Mark A. Dawson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vathiotis, Ioannis, Avisek Banerjee, Utsav Sen, et al.. (2025). Histologic Transformation in Cancer: The Path for Clinical Translation. Cancer Discovery. 15(9). 1783–1793.
2.
Kulkarni, Aishwarya, Leonard Post, Yih-Chih Chan, et al.. (2024). Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription. EMBO Reports. 25(9). 3944–3969. 5 indexed citations
3.
Handunnetti, Sasanka M., Mary Ann Anderson, Kate Burbury, et al.. (2024). Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 144(8). 867–872. 7 indexed citations
4.
Biben, Christine, Tom Weber, Kathryn Potts, et al.. (2023). In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis. Nature Communications. 14(1). 41–41. 20 indexed citations
5.
Gilan, Omer, Charles C. Bell, Kathy Knezevic, et al.. (2023). CRISPR–ChIP reveals selective regulation of H3K79me2 by Menin in MLL leukemia. Nature Structural & Molecular Biology. 30(10). 1592–1606. 12 indexed citations
6.
Hogg, Simon J., Paul A. Beavis, Mark A. Dawson, & Ricky W. Johnstone. (2020). Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery. 19(11). 776–800. 461 indexed citations breakdown →
7.
Guirguis, Andrew A., Brian Liddicoat, & Mark A. Dawson. (2020). The old and the new: DNA and RNA methylation in normal and malignant hematopoiesis. Experimental Hematology. 90. 1–11. 4 indexed citations
8.
Marine, Jean‐Christophe, Sarah‐Jane Dawson, & Mark A. Dawson. (2020). Non-genetic mechanisms of therapeutic resistance in cancer. Nature reviews. Cancer. 20(12). 743–756. 353 indexed citations breakdown →
9.
House, Imran G., Colin M. House, A. J. Brennan, et al.. (2017). Regulation of perforin activation and pre‐synaptic toxicity through C‐terminal glycosylation. EMBO Reports. 18(10). 1775–1785. 28 indexed citations
10.
Tögel, Lars, Anderly C. Chüeh, Aparna Jayachandran, et al.. (2016). Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Molecular Cancer Therapeutics. 15(6). 1217–1226. 74 indexed citations
11.
Tam, Constantine S., Andrew W. Roberts, Mary Ann Anderson, et al.. (2016). The combination of ibrutinib and venetoclax (ABT-199) rapidly achieves complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study. Haematologica. 3 indexed citations
12.
Tchasovnikarova, Iva A., Richard T. Timms, Nicholas J. Matheson, et al.. (2015). Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells. Science. 348(6242). 1481–1485. 225 indexed citations
13.
Barbieri, Ilaria, Emanuele Cannizzaro, & Mark A. Dawson. (2013). Bromodomains as therapeutic targets in cancer. Briefings in Functional Genomics. 12(3). 219–230. 63 indexed citations
14.
Dawson, Mark A., Jayne Curry, Philip Beer, et al.. (2010). AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. British Journal of Haematology. 150(1). 46–57. 41 indexed citations
15.
Dawson, Mark A., Stephen Opat, Yamna Taouk, et al.. (2009). Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma. Clinical Cancer Research. 15(2). 714–722. 25 indexed citations
16.
Hurd, Paul J., Andrew J. Bannister, Karen Halls, et al.. (2009). Phosphorylation of Histone H3 Thr-45 Is Linked to Apoptosis. Journal of Biological Chemistry. 284(24). 16575–16583. 92 indexed citations
17.
Wilson, Nicola K., Diego Miranda‐Saavedra, Sarah Kinston, et al.. (2009). The transcriptional program controlled by the stem cell leukemia gene Scl/Tal1 during early embryonic hematopoietic development. Blood. 113(22). 5456–5465. 100 indexed citations
18.
19.
Bonhaus, Douglas W., Lee A. Flippin, Robert Greenhouse, et al.. (1999). RS‐127445: a selective, high affinity, orally bioavailable 5‐HT2B receptor antagonist. British Journal of Pharmacology. 127(5). 1075–1082. 95 indexed citations
20.
Dawson, Mark A. & J. Larry Renfro. (1993). Interaction of structurally similar pesticides with organic anion transport by primary cultures of winter flounder renal proximal tubule.. Journal of Pharmacology and Experimental Therapeutics. 266(2). 673–677. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jordan S. Fridman Breakdown of academic impact, for papers by Richard B. Lock Breakdown of academic impact, for papers by Donald L. Durden Breakdown of academic impact, for papers by Joel Johansson Breakdown of academic impact, for papers by Alwin Krämer Breakdown of academic impact, for papers by Peter Atadja Breakdown of academic impact, for papers by Edward A. Fox Breakdown of academic impact, for papers by Isidro Sánchez‐García Breakdown of academic impact, for papers by Domenico Delia Breakdown of academic impact, for papers by Selina Chen‐Kiang
Rankless by CCL
2026